Overview

Description

  • NatureSynthetic

Specifications

Our Abpromise guarantee covers the use of ab45233 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General info

  • Alternative names
    • 5330426P09Rik
    • 9030416C10Rik
    • Aberrant WW domain-containing oxidoreductase
    • D16S432E
    • EC 1.1.1.-
    • FOR
    • FRA16D
    • Fragile site FRA16D oxidoreductase
    • Fragile site FRA16D Oxireductase
    • HHCMA56
    • MGC55975
    • PRO0128
    • Putative oxidoreductase
    • SDR41C1
    • Short chain dehydrogenase/reductase family 41C, member 1
    • WOX1
    • WW domain containing oxidoreductase
    • WW domain-containing oxidoreductase
    • WW domain-containing protein WWOX
    • wwox
    • WWOX_HUMAN
    • zgc:55975
    see all
  • FunctionPutative oxidoreductase. Acts as a tumor suppressor and plays a role in apoptosis. Required for normal bone development (By similarity). May function synergistically with p53/TP53 to control genotoxic stress-induced cell death. Plays a role in TGFB1 signaling and TGFB1-mediated cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death. Inhibits Wnt signaling, probably by sequestering DVL2 in the cytoplasm.
  • Tissue specificityWidely expressed. Strongly expressed in testis, prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and isoform 6 may only be expressed in tumor cell lines.
  • Involvement in diseaseNote=Defects in WWOX may be involved in several cancer types. The gene spans the second most common chromosomal fragile site (FRA16D) which is frequently altered in cancers. Alteration of the expression and expression of some isoforms is associated with cancers. However, it is still unclear if alteration of WWOX is directly implicated in cancerogenesis or if it corresponds to a secondary effect.
    Defects in WWOX may be a cause of esophageal cancer (ESCR) [MIM:133239].
  • Sequence similaritiesBelongs to the short-chain dehydrogenases/reductases (SDR) family.
    Contains 2 WW domains.
  • DomainThe WW 1 domain mediates interaction with TP53, and probably TP73, TFAP2C, LITAF and WBP1.
  • Post-translational
    modifications
    Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 regulates interaction with TP53, TP73 and MAPK8. May also regulate proapoptotic activity. Phosphorylation by TNK2 is associated with polyubiquitination and degradation.
    Ubiquitinated when phosphorylated by TNK2, leading to its degradation.
  • Cellular localizationCytoplasm. Nucleus. Mitochondrion. Golgi apparatus. Partially localizes to the mitochondria. Translocates to the nucleus upon genotoxic stress or TNF stimulation (By similarity). Translocates to the nucleus in response to TGFB1. Isoform 5 and isoform 6 may localize in the nucleus.
  • Information by UniProt

References for Human WWOX peptide (ab45233)

ab45233 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab45233.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"